Search
chlorpheniramine/phenylephrine/phenylpropanolamine/phenyltoloxamine (Naldecon, Naldelate, Par Decon)
Indications:
1) symptomatic treatment of nasal & eustachian tube congestion associated with sinusitis & upper respiratory tract infection
2) symptomatic relief of allergic rhinitis
Contraindications:
1) severe hypertension
2) coronary artery disease
3) concurrent MAO inhibitor therapy
Dosage:
1) adults & children > 12 years: 1 tab TID
2) children 6-12 years: 2.5 mL of syrup every 3-4 hours
Tabs: (sustained release)
phenylpropanolamine HCl 40 mg, chlorpheniramine maleate 5 mg
phenyltoloxamine citrate 15 mg & phenylephrine HCl 10 mg
Syrup:
phenylpropanolamine HCl 20 mg, chlorpheniramine maleate 2.5 mg
phenyltoloxamine citrate 7.5 mg & phenylephrine HCl 5 mg/5 mL Pediatric syrup:
phenylpropanolamine HCl 5 mg, chlorpheniramine maleate 0.5 mg
phenyltoloxamine citrate 2 mg & phenylephrine HCl 1.25 mg/5 mL
Adverse effects:
1) drowsiness
2) sedation
3) dizziness
Interactions
drug interactions
General
Ear nose throat combination
Database Correlations
PUBCHEM cid=196241
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
Components
chlorpheniramine (Chlor-Trimeton)
phenylephrine (Neo-Synephrine, Mydrifin, sudafed PE, PE)
phenylpropanolamine (PPA)
phenyltoloxamine